| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0510-83588313-811 18800520310 |
| Email: |
sales@chemshuttle.com |
| Products Intro: |
Product Name:7-hydroxy-6-methoxy-4-methyl-3-(2-morpholino-2-oxoethyl)-2-oxo-2H-chromene-8-carbaldehyde
CAS:1338934-59-0
Purity:95% Package:5mg;25mg;100mg;500mg;1g;5g;10g;25g;50g;100g;250g;500g;kg…
|
MKC8866 manufacturers
- MKC8866
-
- $80.00
-
2026-06-02
- CAS:1338934-59-0
- Purity: 99.85%
- Supply Ability: 10g
|
| | MKC8866 Basic information |
| Product Name: | MKC8866 | | Synonyms: | MKC8866;2H-1-Benzopyran-8-carboxaldehyde, 7-hydroxy-6-methoxy-4-methyl-3-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-;IRE1 RNase inhibitor 8866
(MKC8866;7-hydroxy-6-methoxy-4-methyl-3-(2-morpholino-2-oxoethyl)-2-oxo-2H-chromene-8-carbaldehyde;MKC8866;MKC-8866;181697;IRE1 RNase inhibitor 8866;Inositol requiring enzyme 1,inhibit,MKC-8866,IRE1,MKC8866,Inhibitor,MKC 8866 | | CAS: | 1338934-59-0 | | MF: | C18H19NO7 | | MW: | 361.35 | | EINECS: | | | Product Categories: | | | Mol File: | 1338934-59-0.mol |  |
| | MKC8866 Chemical Properties |
| Boiling point | 620.0±55.0 °C(Predicted) | | density | 1.373±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:16.67(Max Conc. mg/mL);46.13(Max Conc. mM) | | form | A solid | | pka | 6.20±0.20(Predicted) | | color | Light yellow to yellow |
| | MKC8866 Usage And Synthesis |
| Uses | MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM[1]. MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth[2]. | | Biological Activity | MKC8866 (IRE1-IN-8866) is a salicylaldehyde analog, a specific IRE1α RNase inhibitor with IC50 of 0.29 μM against human IRE1α in vitro. | | in vivo | MKC8866 (oral ; 300 mg/kg; for 28 days) reduces tumor regrowth post-NSC 125973 withdrawal[1]. | Animal Model: | Female athymic nude mice with MDA-MB-231 tumor[1] | | Dosage: | 300 mg/kg | | Administration: | Oral; for 28 days | | Result: | Reduced tumor regrowth post-NSC 125973 withdrawal.
|
| | target | | Target | Value | hIRE1α
(Cell-free assay) | 0.29 μM |
| | References | [1] Sheng X, et al. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019 Jan 24;10(1):323. DOI:10.1038/s41467-018-08152-3
[2] Logue SE, et al. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat Commun. 2018 Aug 15;9(1):3267. DOI:10.1038/s41467-018-05763-8 |
| | MKC8866 Preparation Products And Raw materials |
|